(Q53589062)

15 May 2018

title

Generalisation from phase III clinical trials: survival, quality of life, and health economics. (English)

1 reference

15 May 2018

main subject

phase III clinical trial

0 references

1 reference

1

1 reference

15 May 2018

author name string

D J Hand

series ordinal

2

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 October 1997

1 reference

15 May 2018

published in

The Lancet

1 reference

15 May 2018

volume

350

1 reference

15 May 2018

issue

9083

1 reference

15 May 2018

page(s)

1025-1027

1 reference

15 May 2018

Generalizing the results of randomized clinical trials

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

From clinical trials to clinical practice: generalizing from participant to patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Generalizing from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Can overall results of clinical trials be applied to all patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Centralised treatment, entry to trials and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Survival of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Management of malignant teratoma: does referral to a specialist unit matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Which patients may be harmed by good treatments?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

1 reference

7 January 2021

Nonspecific effects in longitudinal studies: impact on quality of life measures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Effects of framing and level of probability on patients' preferences for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Whose utilities for decision analysis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Cost-effectiveness analysis: sleeping with an enemy or a friend?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

Quality of life measures in health care. III: Resource allocation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2903053-5

7 January 2021

10.1016/S0140-6736(97)03053-5

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018